Is Procalcitonin-Guided Antimicrobial Use Cost-Effective in Adult Patients with Suspected Bacterial Infection and Sepsis?

被引:32
作者
Harrison, Michelle [1 ]
Collins, Curtis D. [1 ]
机构
[1] St Joseph Mercy Hlth Syst, Dept Pharm Serv, Ann Arbor, MI 48106 USA
关键词
VANCOMYCIN-INDUCED NEPHROTOXICITY; VENTILATOR-ASSOCIATED PNEUMONIA; RESPIRATORY-TRACT INFECTIONS; INTENSIVE-CARE PATIENTS; ANTIBIOTIC-THERAPY; LENGTH; METAANALYSIS; ALGORITHMS; EXPOSURE; IMPACT;
D O I
10.1017/ice.2014.60
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE. Procalcitonin has emerged as a promising biomarker of bacterial infection. Published literature demonstrates that use of procalcitonin testing and an associated treatment pathway reduces duration of antibiotic therapy without impacting mortality. The objective of this study was to determine the financial impact of utilizing a procalcitonin-guided treatment algorithm in hospitalized patients with sepsis. DESIGN. Cost-minimization and cost-utility analysis. PATIENTS. Hypothetical cohort of adult ICU patients with suspected bacterial infection and sepsis. METHODS. Utilizing published clinical and economic data, a decision analytic model was developed from the U. S. hospital perspective. Effectiveness and utility measures were defined using cost-per-clinical episode and cost per quality-adjusted life years (QALYs). Upper and lower sensitivity ranges were determined for all inputs. Univariate and probabilistic sensitivity analyses assessed the robustness of our model and variables. Incremental cost-effectiveness ratios (ICERs) were calculated and compared to predetermined willingness-to-pay thresholds. RESULTS. Base-case results predicted the use of a procalcitonin-guided treatment algorithm dominated standard care with improved quality (0.0002 QALYs) and decreased overall treatment costs ($65). The model was sensitive to a number of key variables that had the potential to impact results, including algorithm adherence (<42.3%), number and cost of procalcitonin tests ordered (>= 9 and >$46), days of antimicrobial reduction (<1.6 d), incidence of nephrotoxicity and rate of nephrotoxicity reduction. CONCLUSION. The combination of procalcitonin testing with an evidence-based treatment algorithm may improve patients' quality of life while decreasing costs in ICU patients with suspected bacterial infection and sepsis; however, results were highly dependent on a number of variables and assumptions.
引用
收藏
页码:265 / 272
页数:8
相关论文
共 36 条
[1]  
Albrich WC, 2012, ARCH INTERN MED, V172, P715, DOI 10.1001/archinternmed.2012.770
[2]   Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis [J].
Angus, DC ;
Linde-Zwirble, WT ;
Clermont, G ;
Ball, DE ;
Basson, BR ;
Ely, EW ;
Laterre, PF ;
Vincent, JL ;
Bernard, G ;
van Hout, B .
CRITICAL CARE MEDICINE, 2003, 31 (01) :1-11
[3]  
[Anonymous], CRIT CARE MED
[4]  
[Anonymous], CONS PRIC IND ALL UR
[5]  
[Anonymous], 2008, AM J RESP CRIT CARE, DOI DOI 10.1164/rccm.200708-1238OC
[6]   Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial [J].
Bouadma, Lila ;
Luyt, Charles-Edouard ;
Tubach, Florence ;
Cracco, Christophe ;
Alvarez, Antonio ;
Schwebel, Carole ;
Schortgen, Frederique ;
Lasocki, Sigismond ;
Veber, Benoit ;
Dehoux, Monique ;
Bernard, Maguy ;
Pasquet, Blandine ;
Regnier, Bernard ;
Brun-Buisson, Christian ;
Chastre, Jean ;
Wolff, Michel .
LANCET, 2010, 375 (9713) :463-474
[7]   Comparison of the Incidence of Vancomycin-Induced Nephrotoxicity in Hospitalized Patients with and without Concomitant Piperacillin-Tazobactam [J].
Burgess, Lindsey D. ;
Drew, Richard H. .
PHARMACOTHERAPY, 2014, 34 (07) :670-676
[8]   Incidence of Nephrotoxicity and Association With Vancomycin Use in Intensive Care Unit Patients With Pneumonia: Retrospective Analysis of the IMPACT-HAP Database [J].
Cano, Ennie L. ;
Haque, Nadia Z. ;
Welch, Verna L. ;
Cely, Cynthia M. ;
Peyrani, Paula ;
Scerpella, Ernesto G. ;
Ford, Kimbal D. ;
Zervos, Marcus J. ;
Ramirez, Julio A. ;
Kett, Daniel H. .
CLINICAL THERAPEUTICS, 2012, 34 (01) :149-157
[9]  
Centers for Medicare and Medicaid Services, 2014, CLIN DIAGN LAB FEE S, DOI DOI 10.1007/s00134-012-2769-8
[10]   Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults - A randomized trial [J].
Chastre, J ;
Wolff, M ;
Fagon, JY ;
Chevret, S ;
Thomas, F ;
Wermert, D ;
Clementi, E ;
Gonzalez, J ;
Jusserand, D ;
Asfar, P ;
Perrin, D ;
Fieux, F ;
Aubas, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (19) :2588-2598